t
Genedrive plc announced that on 28 August 2026, CEO Dr Gino Miele acquired 700,000 Ordinary Shares at 1.38p per share and CFO Russ Shaw acquired 700,000 Ordinary Shares at 1.40p per share. Following these purchases, Dr Miele is interested in 7,902,187 Ordinary Shares, representing 0.49% of the issued share capital, and Mr Shaw holds 8,400,000 Ordinary Shares, representing 0.52%.
| Date | 1 Sept 2026 |
| Time | 07:00:15 |
| Category | Director/PDMR dealings |
| ID | 7656S |
01 September 2026
genedrive plc
("genedrive" or the "Company")
Director/PDMR Notification
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company announces that on 28 August 2026, Dr Gino Miele, Chief Executive Officer, acquired 700,000 Ordinary Shares in the Company at a price of 1.38p per share and Russ Shaw, Chief Financial Officer, acquired 700,000 Ordinary Shares in the Company at a price of 1.40p per share.
Following these purchases, Dr Gino Miele, is interested in 7,902,187 Ordinary Shares, 0.49% of the issued share capital of the Company and Russ Shaw is interested in 8,400,000 Ordinary Shares, 0.52% of the issued share capital of the Company.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
|
1. |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a. |
Name |
1. Dr Gino Miele 2. Russ Shaw
|
||||
|
2. |
Reason for the notification |
|||||
|
a. |
Position/status |
1. Chief Executive Officer 2. Chief Financial Officer
|
||||
|
b. |
Initial notification /Amendment |
Initial notification |
||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a. |
Name |
genedrive plc |
||||
|
b. |
LEI |
213800ZYODIRZ87Y4K14 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a. |
Description of the Financial instrument, type of instrument Identification code |
Ordinary Shares of 0.015p each
GB00B1VKB244 |
||||
|
b. |
Nature of the transaction |
Purchase of ordinary shares |
||||
|
c. |
Price(s) and volume(s) |
|
||||
|
d. |
Aggregated information · Aggregated volume · Price
|
1. £9,660.00 2. £9,800.00
|
||||
|
e. |
Date of the transaction |
28 August 2026 |
||||
|
f. |
Place of the transaction |
London Stock Exchange, AIM Market (XLON)
|
||||
|
genedrive plc |
+44 (0)161 989 0245 |
|
Gino Miele: CEO / Russ Shaw: CFO |
https://investors.genedrive.com/s/e0025c
|
|
|
|
|
Peel Hunt LLP (Nominated Adviser and Broker) |
+44 (0)20 7418 8900 |
|
James Steel |
|
|
|
|
|
5654 & Company (Media & Investor Relations) |
|
|
Matthew Neal |
+44 (0)7917 800 011 |
|
Melissa Gardiner |
+44 (0)7757 697357 |
Subscribe to our news alert service: https://investors.genedrive.com/s/efea03
About genedrive plc (http://www.genedrive.com).
genedrive plc is a UK-based, commercial-stage pharmacogenetic testing company focused on rapid, point-of-care diagnostic tests to guide safe and effective drug prescription in emergency and acute care settings.
genedrive's proprietary technology platform enables clinicians to prescribe safer and more effective therapies based on a patient's genetic profile, supporting improved outcomes while reducing pressure on healthcare systems, lowering downstream healthcare costs through the prevention of avoidable complications and earlier, more effective intervention
The Company has two CE-IVD approved and NICE-recommended tests in NHS clinical use. The Genedrive® CYP2C19 ID Kit identifies stroke patients who will not respond to the current standard of care, Clopidogrel, used to reduce risk of secondary stroke. The Genedrive® MT-RNR1 ID Kit helps prevent antibiotic-induced hearing loss (AIHL) in newborns, enabling treatment decisions within actionable timeframes at the point of care.
Headquartered in Manchester, genedrive is focused on scaling UK-developed precision diagnostics within routine care and leveraging real-world evidence to support broader international adoption and commercial growth.